SAN MATEO, Calif. — November 20, 2025 — Leads & Copy — Sagimet Biosciences Inc. (Nasdaq: SGMT) will participate in the 8th Annual Evercore ISI Healthcare Conference on December 2, 2025, in Coral Gables, Florida.
Management will host a fireside chat at 12:55 p.m. ET. A live webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website. An archived replay will be available for 90 days following the event.
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways. These pathways are found in conditions resulting from the overproduction of palmitate, a fatty acid.
Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH. It also met all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne.
A combination of denifanstat and resmetirom is currently being tested in a Phase 1 PK clinical trial. It is planned to be developed for cirrhotic patients living with F4-stage MASH. TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Advisors
mfitzhugh@lifescicomms.com
Source: Sagimet Biosciences
